Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Fu-Xiang Ran"'
Autor:
Xu Han, Long-Long Si, Yong-Ying Shi, Zi-Bo Fan, Shou-Xin Wang, Zhen-Yu Tian, Man Li, Jia-Qi Sun, Ping-Xuan Jiao, Fu-Xiang Ran, Yong-Min Zhang, De-Min Zhou, Su-Long Xiao
Publikováno v:
Molecules, Vol 22, Iss 7, p 1018 (2017)
The emergence of drug resistant variants of the influenza virus has led to a great need to identify novel and effective antiviral agents. In our previous study, a series of sialic acid (C-2 and C-4)-pentacyclic triterpene conjugates have been synthes
Externí odkaz:
https://doaj.org/article/e1c25ba81e5947d99143382967ad2ef8
Publikováno v:
Journal of Cancer
YSY01A is a new tripeptideboronic acid and an analog of PS341. However, YSY01A's antitumor effects and mechanism have not yet been elucidated. This study demonstrates that YSY01A inhibited proteasome activity by combining with the chymotrypsin-like (
Autor:
Xia Yuan, Runtao Li, Fu-Xiang Ran, Jingrong Cui, Quan Zhou, Bingjie Xue, Zemei Ge, Bo Xu, Wei Huang, Yaxin Lou
Publikováno v:
Journal of Cancer
Given that the proteasome is essential for multiple cellular processes by degrading diverse regulatory proteins, inhibition of the proteasome has emerged as an attractive target for anti-cancer therapy. YSY01A is a novel small molecule compound targe
Autor:
Xia Yuan, Wei Huang, Runtao Li, Fu-Xiang Ran, Zemei Ge, Ting Sun, Wei Guo, Jingrong Cui, Shujie Fan, Huayu Yang, Quan Zhou, Jun Wang
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 8 (2017)
Frontiers in Pharmacology, Vol 8 (2017)
Proteasome inhibition interfering with many cell signaling pathways has been extensively explored as a therapeutic strategy for cancers. Proteasome inhibitor YSY01A is a novel agent that has shown remarkable anti-tumor effects; however, its mechanism
Publikováno v:
Acta Biochimica et Biophysica Sinica. 44:490-502
Angiogenesis inhibitors combined with chemotherapeutic drugs have significant efficacy in the treatment of a variety of cancers. Pseudolarix acid B (PAB) is a traditional pregnancy-terminating agent, which has previously been shown to reduce tumor gr
Publikováno v:
Acta Biochimica et Biophysica Sinica. 44:136-146
CS-1, a new alkaloid with a molecular formula of C(21)H(20)O(8)N(2)S, is extracted from traditional Chinese medicine. Previous studies have shown that CS-1 can inhibit the proliferation of several human carcinoma cells in vivo and in vitro. The aims
Publikováno v:
Molecular Carcinogenesis. 50:945-960
β-escin, a triterpene saponin, is one of the major active compounds extracted from horse chestnut (Aesculus hippocastanum) seed. Previous work has found that β-escin sodium has antiinflammatory and antitumor effects. In the present study, we invest
Autor:
Ming-Ying Shang, Jie Yu, Xuan Wang, Shao-Qing Cai, Jing-Rong Cui, Katsuko Komatsu, Rui-Qing Wang, Fu-Xiang Ran, Tsuneo Namba
Publikováno v:
Fitoterapia. 79:293-297
The cytotoxic activity against some tumor cell lines of 16 commonly used species of Asarum was evaluated in this study. All of these plants were widely used in Asian countries as traditional medicines or folk medicines. Their inhibitory activities ag
Autor:
Xia Yuan, Jingrong Cui, Runtao Li, Fu-Xiang Ran, Hua-yu Yang, Guang-liang Qiang, Wei Huang, Quan Zhou, Zemei Ge
Publikováno v:
Journal of Cancer
Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inh
Autor:
Jian Xiao, Yong-Na Lu, Rui-Qing Wang, Fu-Xiang Ran, Lin Yu, Guo-Cang Wang, Jing-Rong Cui, Haibin Song, Jin-Shan Li
Publikováno v:
Journal of Organometallic Chemistry. 690:151-156
A series of novel organoantimony arylhydroxamates with the formulae [Ar 3 SbL 2 ] − [HNEt 3 ] + (LH = arylhydroxamic acid; Ar = C 6 H 5 , 4-CH 3 C 6 H 4 , 3-CH 3 C 6 H 4 , 4-ClC 6 H 4 , 4-FC 6 H 4 ) and (4-CH 3 C 6 H 4 ) 4 SbL were synthesized and